Webinar: Living Better After Cancer - Young Adults Adapting To A New Reality

Submitted by PatientsEngage on 3 May 2019

An insightful panel discussion with two cancer winners and a Psycho Oncologist who talk about the various aspects of cancer survivorship especially among young adults.  

The latest in our ‘Living Better’ series of Live Q&A sessions looks at the psycho-social aspects of young adults who have to deal with cancer. This session covers how cancer re-defines identity, how it affects relationships and friendships, equations at work and perspectives in life.

Listen to an insightful and interesting session with Psycho Oncologist Aneri Shah and Cancer survivors Gauri and Pranay as they tackle a wide ranging set of topics:

  • Handling the "Why Me" phase and their advice to others going through this 
  • Cancer patients struggle with letting friends and colleagues see them while they are going through treatment. How should they decide what is appropriate?
  • Suggestions for friends and families of cancer patients. Should they talk about cancer? What could they say? What should they not say/do?
  • Handling the challenges of returning to work during and after the treatment
  • Impact of cancer journey on perspective on work and life
  • Guidance for childhood cancer survivors - should they talk about it when making new friends
  • Appropriate time to share/disclose the cancer experience during dating. 
  • Effect of cancer on existing marriages and marriage prospects. Advice to patients and families
  • Cancer and stigma 
  • Most patients go through a lot of fear, insomnia, anxiety. Tips on handling this. 
  • Regaining energies after cancer and getting back to doing the things one loves.
  •  

 

Community
Cancer
Condition
Cancer
Lymphoma
Changed
Fri, 05/03/2019 - 20:18

Stories

  • Chemotherapy explained in Hindi
    Do not fear Chemotherapy ! Understand Chemotherapy and how to deal with it. A great video in Hindi by SanjeevaniLifeBeyondCancer  
  • Novel Immunotherapy Vaccine Decreases Recurrence in HER2 Breast Cancer Patients
    Women with breast cancer tumors that overexpress human epidermal growth factor receptor 2 (HER2) may benefit from a novel vaccine to prevent recurrence A new breast cancer vaccine candidate, (GP2), provides further evidence of the potential of immunotherapy in preventing disease recurrence. One of only a few vaccines of its kind in development, GP2 has been shown to be safe and effective for breast cancer patients, reducing recurrence rates by 57%. Further, women with the highest overexpression…
  • My cancer doesn't define who I am
    "I was originally diagnosed with locally advanced cancer, so that means it's advanced within in the chest. Mine was triple negative. It's the most aggressive form of cancer," she said. Her breast cancer diagnosis came in 2008. She found out about her metastatic breast cancer in January 2011, at 33 years old. "Two and half years after my original diagnosis, I found another lump," she said as she held back tears. "It varies from person to person. But my experience has been a bit of a roller…
  • Joan Lunden talks about her Breast Cancer
    How she shared the information with her kids and why - http://www.today.com/health/joan-lunden-how-i-told-my-kids-i-have-cancer-2D80186889 The choices she made in terms of treatment - http://www.people.com/article/joan-lunden-chemotherapy-cancer
  • Did you know that womb cancer is the fourth most common cancer in women ?
    My cancer could have been caught earlier if I had been alerted about spotting between periods, heavy periods and watery blood between periods as the main symptoms of womb cancer,” she says. But when she asked NHS Choices whether there should be mention of womb cancer on the menopause pages, she received the following reply: “The problem with adding a warning about womb cancer to the menopause pages is that it may cause unnecessary panic.” And this, says Widschwendter, is the nub of the problem…
  • U.S. FDA Approves New Indication for the Use of Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer
    The FDA initially approved XTANDI, an oral, once-daily androgen receptor inhibitor, in August 2012 for use in patients with metastatic CRPC who previously received docetaxel (chemotherapy). The new indication approves XTANDI for use in men with metastatic CRPC who have not received chemotherapy. Metastatic CRPC is defined as a cancer that has spread beyond the prostate gland and has progressed despite treatment to lower testosterone (i.e., with a gonadotropin-releasing hormone (GnRH) therapy or…
  • Heal Your Cancer
    Don’t fight cancer, heal it by attending to body, mind and spirit, says surgical oncologist Dr Vishal Rao. A child developing from an embryo in a mother’s womb is, in reality, a set of rapidly multiplying cells. But they are controlled and regulated. So, we choose to ‘love’ those cells. But when another set of cells multiply rapidly within our body, albeit haphazardly, we call it ‘Cancerous’! These cells are not foreign cells that have made an appearance from outside,…
  • “I was open to anything, just trying to find things to help me stay alive,” said Geoffrey Boycott
    Geoffrey Boycott describes how counting off his radiotherapy sessions like runs in cricket and Feng Shui helped him survive cancer http://www.telegraph.co.uk/sport/cricket/11080199/Geoffrey-Boycott-reve…
  • FDA approves first non-invasive home based DNA screening test for colorectal cancer
    The U.S. Food and Drug Administration approved Cologuard, the first stool-based colorectal screening test that detects the presence of red blood cells and DNA mutations that may indicate the presence of certain kinds of abnormal growths that may be cancers such as colon cancer or precursors to cancer. Cologuard offers people 50 and older at average risk for colorectal cancer an easy-to-use screening test they can do in the privacy of their own home. Colorectal cancer was the third most…
  • Mayo Clinic partners with IBM to match Cancer Patients with Clinical Trials
    Mayo Clinic unveiled today a partnership with IBM to harness the power of its Watson supercomputer to match patients with the right clinical trials. Starting early next year, Watson will initially enroll patients with breast, colorectal and lung cancers based on eligibility. There are 170,000 ongoing clinical trials around the world, however, according to the Center for Information and Study on Clinical Research Participation, only 6% are completed on time. Enrolling patients in the…